Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9360122 | 0.93 | MAOB (0.64) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL870305 | 0.91 | CYP1A2 (0.61) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL2560923 | 0.90 | ALDH1A1 (0.59) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5692419 | 0.90 | CYP1A2 (0.59) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL321661 | 0.89 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL3445140 | 0.85 | CHRNB2 (0.55) | MAOBMAOABCHEACHEKDM4E | |
| SCHEMBL272824 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL510500 | 0.83 | ALDH1A1 (0.73) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5693237 | 0.83 | ALDH1A1 (0.61) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL30186025 | 0.82 | BCHE (0.70) | ALDH1A1MAPTHPGDMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427713-A1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | Astrazeneca AB (SE) | 2004-06-16 | — | — | EP | claimed |
| WO-2003022825-A1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | claimed |
| CN-113454086-B | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119350257-A | Triazole compounds | 广西医科大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-115594642-B | A Ji Ruige triazole derivative and application thereof in resisting breast cancer | 广西医科大学 | 2024-12-27 | — | — | CN | disclosed |
| CN-115594642-A | Az Ji Ruige triazole derivative and application thereof in resisting breast cancer | 广西医科大学（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115433592-A | Salt-tolerant high-foam high-internal phase emulsion stabilizer and preparation method thereof | 江南大学 | 2022-12-06 | — | — | CN | disclosed |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | BEAVERS LISA SELSAM (US) | 2004-06-10 | — | — | US | disclosed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | disclosed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| EP-0863877-A4 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INST (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0863877-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997016428-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | ALDH1A1 3404/4885LMNA 989/4885MAPT 526/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | ALDH1A1 3202/4885LMNA 990/4885MAPT 406/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | ALDH1A1 3093/4885LMNA 943/4885MAPT 430/4885 |
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | ALDH1A1 472/4885LMNA 4659/4885MAPT 4067/4885 |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | ALDH1A1 3093/4885LMNA 943/4885MAPT 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.